55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability ...
The last time I spoke about Shattuck Labs (STTK), it was with a Seeking Alpha article entitled "Shattuck Labs: "Hold" On Oncology Exit And Competitive TL1A/DR3 Pathway Pivot." With respect to this ...
Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignancies An ORR of 100% (6/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results